Holocene Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Holocene Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-360,000	Closed	-$9.29M	–	810
2021 Q1	$9.29M	Buy	+360,000	New	+$15.8M	0.06%	217

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Holocene Advisors's ACAD Position: Q3 2022 in Review

Holocene Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 50,607 shares — an estimated $713K sold.

Holocene Advisors first reported a position in ACAD in Q4 2017 and held it in 3 quarters. The position peaked at $713K in Q2 2022. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

Holocene Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Holocene Advisors sold 50,607 Acadia Pharmaceuticals shares in Q3 2022, an estimated $713K.
Holocene Advisors first reported a position in Acadia Pharmaceuticals in Q4 2017 and held it in 3 quarters.
Holocene Advisors's Acadia Pharmaceuticals position peaked at $713K in Q2 2022.
223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Holocene Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.